nodes	percent_of_prediction	percent_of_DWPC	metapath
Pyrazinamide—CYP1A2—Imiquimod—skin cancer	0.213	0.249	CbGbCtD
Pyrazinamide—CYP1A2—Vemurafenib—skin cancer	0.117	0.137	CbGbCtD
Pyrazinamide—CYP3A4—Imiquimod—skin cancer	0.111	0.131	CbGbCtD
Pyrazinamide—CYP3A4—Temozolomide—skin cancer	0.111	0.131	CbGbCtD
Pyrazinamide—CYP1A2—Dacarbazine—skin cancer	0.0893	0.105	CbGbCtD
Pyrazinamide—CYP3A4—Vismodegib—skin cancer	0.0773	0.0906	CbGbCtD
Pyrazinamide—CYP3A4—Vemurafenib—skin cancer	0.0611	0.0716	CbGbCtD
Pyrazinamide—CYP1A2—Fluorouracil—skin cancer	0.0524	0.0614	CbGbCtD
Pyrazinamide—CYP3A4—Docetaxel—skin cancer	0.021	0.0246	CbGbCtD
Pyrazinamide—Clotting—Temozolomide—skin cancer	0.00524	0.0357	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Vemurafenib—skin cancer	0.00474	0.0323	CcSEcCtD
Pyrazinamide—Gout—Imiquimod—skin cancer	0.00334	0.0228	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Vemurafenib—skin cancer	0.00333	0.0227	CcSEcCtD
Pyrazinamide—Photosensitivity—Vemurafenib—skin cancer	0.00302	0.0206	CcSEcCtD
Pyrazinamide—Hepatomegaly—Dactinomycin—skin cancer	0.00292	0.0199	CcSEcCtD
Pyrazinamide—Digestion impaired—Temozolomide—skin cancer	0.0028	0.0191	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Dactinomycin—skin cancer	0.00268	0.0182	CcSEcCtD
Pyrazinamide—Coagulopathy—Dactinomycin—skin cancer	0.00266	0.0181	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Temozolomide—skin cancer	0.00242	0.0165	CcSEcCtD
Pyrazinamide—Coagulopathy—Temozolomide—skin cancer	0.0024	0.0164	CcSEcCtD
Pyrazinamide—Arthralgia—Vismodegib—skin cancer	0.0022	0.015	CcSEcCtD
Pyrazinamide—Myalgia—Vismodegib—skin cancer	0.0022	0.015	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Vemurafenib—skin cancer	0.0021	0.0143	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00193	0.0131	CcSEcCtD
Pyrazinamide—Dyspepsia—Vismodegib—skin cancer	0.00186	0.0127	CcSEcCtD
Pyrazinamide—Decreased appetite—Vismodegib—skin cancer	0.00184	0.0125	CcSEcCtD
Pyrazinamide—Dysuria—Imiquimod—skin cancer	0.00183	0.0125	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Vismodegib—skin cancer	0.00182	0.0124	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Imiquimod—skin cancer	0.00179	0.0122	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Docetaxel—skin cancer	0.00161	0.011	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Fluorouracil—skin cancer	0.00157	0.0107	CcSEcCtD
Pyrazinamide—Pruritus—Vismodegib—skin cancer	0.00149	0.0102	CcSEcCtD
Pyrazinamide—Photosensitivity—Fluorouracil—skin cancer	0.00142	0.00971	CcSEcCtD
Pyrazinamide—Myalgia—Vemurafenib—skin cancer	0.00136	0.00928	CcSEcCtD
Pyrazinamide—Arthralgia—Vemurafenib—skin cancer	0.00136	0.00928	CcSEcCtD
Pyrazinamide—Vomiting—Vismodegib—skin cancer	0.00134	0.00915	CcSEcCtD
Pyrazinamide—Rash—Vismodegib—skin cancer	0.00133	0.00908	CcSEcCtD
Pyrazinamide—Dermatitis—Vismodegib—skin cancer	0.00133	0.00907	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Imiquimod—skin cancer	0.00127	0.00862	CcSEcCtD
Pyrazinamide—Nausea—Vismodegib—skin cancer	0.00126	0.00855	CcSEcCtD
Pyrazinamide—Malaise—Imiquimod—skin cancer	0.00123	0.00838	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00119	0.0081	CcSEcCtD
Pyrazinamide—Arthralgia—Imiquimod—skin cancer	0.00116	0.00791	CcSEcCtD
Pyrazinamide—Myalgia—Imiquimod—skin cancer	0.00116	0.00791	CcSEcCtD
Pyrazinamide—Discomfort—Imiquimod—skin cancer	0.00115	0.00782	CcSEcCtD
Pyrazinamide—Decreased appetite—Vemurafenib—skin cancer	0.00113	0.00773	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00113	0.00768	CcSEcCtD
Pyrazinamide—Dysuria—Temozolomide—skin cancer	0.0011	0.00748	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Temozolomide—skin cancer	0.00107	0.0073	CcSEcCtD
Pyrazinamide—Anorexia—Imiquimod—skin cancer	0.00106	0.00723	CcSEcCtD
Pyrazinamide—Hepatitis—Dactinomycin—skin cancer	0.00104	0.00707	CcSEcCtD
Pyrazinamide—Body temperature increased—Vemurafenib—skin cancer	0.00103	0.00703	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00101	0.00691	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Fluorouracil—skin cancer	0.000987	0.00672	CcSEcCtD
Pyrazinamide—Dyspepsia—Imiquimod—skin cancer	0.00098	0.00668	CcSEcCtD
Pyrazinamide—Decreased appetite—Imiquimod—skin cancer	0.000968	0.00659	CcSEcCtD
Pyrazinamide—Hypersensitivity—Vemurafenib—skin cancer	0.000962	0.00655	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Imiquimod—skin cancer	0.000961	0.00655	CcSEcCtD
Pyrazinamide—Hepatitis—Temozolomide—skin cancer	0.000939	0.0064	CcSEcCtD
Pyrazinamide—Pruritus—Vemurafenib—skin cancer	0.000924	0.00629	CcSEcCtD
Pyrazinamide—Feeling abnormal—Imiquimod—skin cancer	0.000917	0.00625	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Bleomycin—skin cancer	0.000899	0.00613	CcSEcCtD
Pyrazinamide—Urticaria—Imiquimod—skin cancer	0.000884	0.00603	CcSEcCtD
Pyrazinamide—Body temperature increased—Imiquimod—skin cancer	0.00088	0.006	CcSEcCtD
Pyrazinamide—Malaise—Bleomycin—skin cancer	0.000874	0.00596	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Dactinomycin—skin cancer	0.000839	0.00571	CcSEcCtD
Pyrazinamide—Vomiting—Vemurafenib—skin cancer	0.00083	0.00566	CcSEcCtD
Pyrazinamide—Myalgia—Bleomycin—skin cancer	0.000825	0.00562	CcSEcCtD
Pyrazinamide—Rash—Vemurafenib—skin cancer	0.000823	0.00561	CcSEcCtD
Pyrazinamide—Dermatitis—Vemurafenib—skin cancer	0.000822	0.0056	CcSEcCtD
Pyrazinamide—Hypersensitivity—Imiquimod—skin cancer	0.00082	0.00559	CcSEcCtD
Pyrazinamide—Discomfort—Bleomycin—skin cancer	0.000815	0.00555	CcSEcCtD
Pyrazinamide—Malaise—Dactinomycin—skin cancer	0.000815	0.00555	CcSEcCtD
Pyrazinamide—Pruritus—Imiquimod—skin cancer	0.000788	0.00537	CcSEcCtD
Pyrazinamide—Nausea—Vemurafenib—skin cancer	0.000775	0.00528	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Bleomycin—skin cancer	0.000774	0.00528	CcSEcCtD
Pyrazinamide—Myalgia—Dactinomycin—skin cancer	0.000769	0.00524	CcSEcCtD
Pyrazinamide—Discomfort—Dactinomycin—skin cancer	0.00076	0.00518	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Temozolomide—skin cancer	0.000758	0.00517	CcSEcCtD
Pyrazinamide—Anorexia—Bleomycin—skin cancer	0.000754	0.00514	CcSEcCtD
Pyrazinamide—Malaise—Temozolomide—skin cancer	0.000737	0.00502	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Dactinomycin—skin cancer	0.000722	0.00492	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000721	0.00491	CcSEcCtD
Pyrazinamide—Vomiting—Imiquimod—skin cancer	0.000708	0.00482	CcSEcCtD
Pyrazinamide—Anorexia—Dactinomycin—skin cancer	0.000703	0.00479	CcSEcCtD
Pyrazinamide—Rash—Imiquimod—skin cancer	0.000702	0.00478	CcSEcCtD
Pyrazinamide—Dermatitis—Imiquimod—skin cancer	0.000701	0.00478	CcSEcCtD
Pyrazinamide—Arthralgia—Temozolomide—skin cancer	0.000696	0.00474	CcSEcCtD
Pyrazinamide—Myalgia—Temozolomide—skin cancer	0.000696	0.00474	CcSEcCtD
Pyrazinamide—Discomfort—Temozolomide—skin cancer	0.000688	0.00469	CcSEcCtD
Pyrazinamide—Decreased appetite—Bleomycin—skin cancer	0.000688	0.00468	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000672	0.00458	CcSEcCtD
Pyrazinamide—Nausea—Imiquimod—skin cancer	0.000661	0.00451	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Temozolomide—skin cancer	0.000653	0.00445	CcSEcCtD
Pyrazinamide—Feeling abnormal—Bleomycin—skin cancer	0.000652	0.00444	CcSEcCtD
Pyrazinamide—Myalgia—Fluorouracil—skin cancer	0.000641	0.00437	CcSEcCtD
Pyrazinamide—Decreased appetite—Dactinomycin—skin cancer	0.000641	0.00437	CcSEcCtD
Pyrazinamide—Anorexia—Temozolomide—skin cancer	0.000636	0.00433	CcSEcCtD
Pyrazinamide—Discomfort—Fluorouracil—skin cancer	0.000634	0.00432	CcSEcCtD
Pyrazinamide—Urticaria—Bleomycin—skin cancer	0.000628	0.00428	CcSEcCtD
Pyrazinamide—Body temperature increased—Bleomycin—skin cancer	0.000625	0.00426	CcSEcCtD
Pyrazinamide—Hepatitis—Docetaxel—skin cancer	0.000624	0.00426	CcSEcCtD
Pyrazinamide—Feeling abnormal—Dactinomycin—skin cancer	0.000608	0.00414	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000608	0.00414	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Fluorouracil—skin cancer	0.000602	0.0041	CcSEcCtD
Pyrazinamide—Dyspepsia—Temozolomide—skin cancer	0.000587	0.004	CcSEcCtD
Pyrazinamide—Anorexia—Fluorouracil—skin cancer	0.000586	0.00399	CcSEcCtD
Pyrazinamide—Body temperature increased—Dactinomycin—skin cancer	0.000583	0.00397	CcSEcCtD
Pyrazinamide—Hypersensitivity—Bleomycin—skin cancer	0.000583	0.00397	CcSEcCtD
Pyrazinamide—Decreased appetite—Temozolomide—skin cancer	0.00058	0.00395	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Temozolomide—skin cancer	0.000576	0.00392	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00056	0.00382	CcSEcCtD
Pyrazinamide—Pruritus—Bleomycin—skin cancer	0.00056	0.00381	CcSEcCtD
Pyrazinamide—Feeling abnormal—Temozolomide—skin cancer	0.00055	0.00375	CcSEcCtD
Pyrazinamide—Hypersensitivity—Dactinomycin—skin cancer	0.000543	0.0037	CcSEcCtD
Pyrazinamide—Dyspepsia—Fluorouracil—skin cancer	0.000541	0.00369	CcSEcCtD
Pyrazinamide—Decreased appetite—Fluorouracil—skin cancer	0.000534	0.00364	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000531	0.00362	CcSEcCtD
Pyrazinamide—Urticaria—Temozolomide—skin cancer	0.00053	0.00361	CcSEcCtD
Pyrazinamide—Body temperature increased—Temozolomide—skin cancer	0.000527	0.00359	CcSEcCtD
Pyrazinamide—Feeling abnormal—Fluorouracil—skin cancer	0.000507	0.00345	CcSEcCtD
Pyrazinamide—Vomiting—Bleomycin—skin cancer	0.000503	0.00343	CcSEcCtD
Pyrazinamide—Rash—Bleomycin—skin cancer	0.000499	0.0034	CcSEcCtD
Pyrazinamide—Dermatitis—Bleomycin—skin cancer	0.000498	0.00339	CcSEcCtD
Pyrazinamide—Hypersensitivity—Temozolomide—skin cancer	0.000492	0.00335	CcSEcCtD
Pyrazinamide—Urticaria—Fluorouracil—skin cancer	0.000488	0.00333	CcSEcCtD
Pyrazinamide—Body temperature increased—Fluorouracil—skin cancer	0.000486	0.00331	CcSEcCtD
Pyrazinamide—Pruritus—Temozolomide—skin cancer	0.000472	0.00322	CcSEcCtD
Pyrazinamide—Nausea—Bleomycin—skin cancer	0.00047	0.0032	CcSEcCtD
Pyrazinamide—Vomiting—Dactinomycin—skin cancer	0.000469	0.0032	CcSEcCtD
Pyrazinamide—Rash—Dactinomycin—skin cancer	0.000465	0.00317	CcSEcCtD
Pyrazinamide—Arthralgia—Docetaxel—skin cancer	0.000463	0.00315	CcSEcCtD
Pyrazinamide—Myalgia—Docetaxel—skin cancer	0.000463	0.00315	CcSEcCtD
Pyrazinamide—Hypersensitivity—Fluorouracil—skin cancer	0.000453	0.00309	CcSEcCtD
Pyrazinamide—Nausea—Dactinomycin—skin cancer	0.000438	0.00299	CcSEcCtD
Pyrazinamide—Pruritus—Fluorouracil—skin cancer	0.000435	0.00296	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Docetaxel—skin cancer	0.000434	0.00296	CcSEcCtD
Pyrazinamide—Vomiting—Temozolomide—skin cancer	0.000424	0.00289	CcSEcCtD
Pyrazinamide—Anorexia—Docetaxel—skin cancer	0.000423	0.00288	CcSEcCtD
Pyrazinamide—Rash—Temozolomide—skin cancer	0.000421	0.00287	CcSEcCtD
Pyrazinamide—Dermatitis—Temozolomide—skin cancer	0.00042	0.00286	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000404	0.00275	CcSEcCtD
Pyrazinamide—Nausea—Temozolomide—skin cancer	0.000396	0.0027	CcSEcCtD
Pyrazinamide—Vomiting—Fluorouracil—skin cancer	0.000391	0.00266	CcSEcCtD
Pyrazinamide—Dyspepsia—Docetaxel—skin cancer	0.000391	0.00266	CcSEcCtD
Pyrazinamide—Rash—Fluorouracil—skin cancer	0.000388	0.00264	CcSEcCtD
Pyrazinamide—Dermatitis—Fluorouracil—skin cancer	0.000387	0.00264	CcSEcCtD
Pyrazinamide—Decreased appetite—Docetaxel—skin cancer	0.000386	0.00263	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Docetaxel—skin cancer	0.000383	0.00261	CcSEcCtD
Pyrazinamide—Feeling abnormal—Docetaxel—skin cancer	0.000366	0.00249	CcSEcCtD
Pyrazinamide—Nausea—Fluorouracil—skin cancer	0.000365	0.00249	CcSEcCtD
Pyrazinamide—Body temperature increased—Docetaxel—skin cancer	0.000351	0.00239	CcSEcCtD
Pyrazinamide—Hypersensitivity—Docetaxel—skin cancer	0.000327	0.00223	CcSEcCtD
Pyrazinamide—Pruritus—Docetaxel—skin cancer	0.000314	0.00214	CcSEcCtD
Pyrazinamide—Vomiting—Docetaxel—skin cancer	0.000282	0.00192	CcSEcCtD
Pyrazinamide—Rash—Docetaxel—skin cancer	0.00028	0.00191	CcSEcCtD
Pyrazinamide—Dermatitis—Docetaxel—skin cancer	0.000279	0.0019	CcSEcCtD
Pyrazinamide—Nausea—Docetaxel—skin cancer	0.000264	0.0018	CcSEcCtD
